During the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, from 29 May to 2 June, Genentech will present the latest results on ten of its approved cancer and other ongoing investigational medicines, mainly focusing on cancer immunotherapy and personalized medicine. The ASCO meeting highlights the next potential treatments for cancer and showcases the current and most innovative lines of cancer research.
Under the Investigational Line of Genentech’s research, data presented will include the following medicines:
- ALECTINIB
Results for ALK inhibitor ALECTINIB treatment in ALK+ non-small cell lung cancer (NSCLC) patients.
- COBIMETINIB
Results for COBIMETINIB in the treatment of advanced BRAF-mutated melanoma.
- GAZYVA (OBINUTUZUMAB)
Results for GAZYVA (OBINUTUZUMAB) in the treatment of non-Hodgkin’s lymphoma.
- MPDL3280A (ANTI-PDL1)
Results for MPDL3280A (ANTI-PDL1) in the treatment of advanced non-small cell lung cancer (NSCLC) and urothelial bladder cancer (UBC).
- VENETOCLAX
Results for VENETOCLAX in the treatment of relapsed/refractory (R/R) multiple myeloma (MM).
Sandra Horning, M.D., chief medical officer and head of Global Product Development commented, “We’re particularly excited about our data in different types of advanced lung cancer, including pivotal data for alectinib and results of the first randomized study of our investigational immunotherapy, MPDL3280A. These results build upon our long-standing commitment to improve outcomes for people with lung cancer, and we hope these data will help us bring new options to treat this devastating disease.”
Additionally, Genentech will present its latest findings for PERJETA, which targets the HER2 receptor, a protein whose expression is significantly increased in a variety of cancers, and that upon binding to other HER receptors, such as EGFR/HER1, HER3 and HER4, promotes tumor growth and survival. PERJETA prevents HER2 pairing with other receptors and coupled with HERCEPTIN (TRASTUZUMAB), a monoclonal antibody that interferes with the HER2 receptor, complements its activity and enhances the blockade of HER signaling pathways, halting tumor growth.
PERJETA data will focus on its activity as a neoadjuvant (pre-surgery) treatment for people with HER2-positive early breast cancer.
